Our Vision

We are spearheading treatments that use the immune system to eliminate cancer, without chemotherapy or radiation. Our goal is to render today’s therapies obsolete until treating childhood cancer is no different than treating an everyday virus.

Accelerating Progress Toward Cures

  • Goal: Cure Neuroblastoma

    Dr. Julie Park is leading one of the world’s first clinical studies of immunotherapy for neuroblastoma – the deadliest childhood cancer.

  • We Need Your Help

    You can help bring an end to childhood cancer all over the world, by supporting our Strong Against Cancer fundraising initiative.

Participate in Research

Our researchers have started the first round of clinical trials exploring a potential cure.

Help us answer questions about childhood health and illness, and help other children in the future. Learn more.


Developing groundbreaking cancer treatments takes more than just the right ideas. It also takes the right people.

Please visit Seattle Children’s careers page to learn about current openings.

For information about potential opportunities in the Ben Towne Center, email us.

Latest News

Pediatric CAR T-cell immunotherapy trial aims to improve remission rates of leukemia at Children’s National Health System (This story appeared in over 60 news outlets) – Morningstar
Children's National Health System is opening a CAR T-cell immunotherapy trial, PLAT-05, which first launched at Seattle Children’s, for pediatric patients with relapsed positive acute lymphoblastic leukemia. Children’s National and Seattle Children's are both a part of CureWorks, an international collaborative of leading academic children's hospitals determined to accelerate the development of immunotherapy treatments for childhood cancer. "Extending the reach of this clinical trial not only allows patients to be treated in their own community, but it also helps to accelerate our ability to ultimately develop a treatment that enables all kids with cancer to grow up and realize their full potential,” said Dr. Mike Jensen, executive director of CureWorks and director of the Ben Towne Center for Childhood Cancer Research at Seattle Children's Research Institute.

BlueRock Therapeutics establishes key partnerships with leading experts in autoimmune disease (This story appeared in over 55 news outlets) – The Oklahoman
BlueRock Therapeutics, an engineered cell therapy company that aims to develop regenerative medicines for intractable diseases, announced the establishment of partnerships with Dr. Bruce Blazar of the University of Minnesota and Dr. Courtney Crane, principal investigator at the Ben Towne Center for Childhood Cancer Research at Seattle Children's.

New trial uses bispecific CAR T-cell therapy to target pediatric ALL – 07.01.2019 – HemOnc Today
Children’s National Health System will be the second location to enroll patients in a pediatric trial that targets both CD19 and CD22 antigens in pediatric patients with acute lymphoblastic leukemia. The bispecific CD19/CD22 CAR used in the PLAT-05 trial was developed by researchers at Seattle Children’s, a member of CureWorks. “We are thrilled that children on the East Coast will now have access to PLAT-05 at Children’s National, allowing them to participate in the groundbreaking CAR T-cell trial closer to home,” said Dr. Mike Jensen, executive director of CureWorks and director of the Ben Towne Center for Childhood Cancer Research at Seattle Children’s Research Institute.